Lapatinib in combination with capecitabine in the management of ErbB2-positive (HER2-positive) advanced breast cancer

Lapatinib is an oral, reversible, dual inhibitor of epidermal growth factor receptor ErbB1 (EGFR) and human epidermal growth factor receptor type 2 ErbB2 (HER2). Results of a phase III study comparing lapatinib plus capecitabine with capecitabine alone in women with ErbB2-overexpressing advanced bre...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Kaufman, Bella, Stein, Steven, Casey, Michelle A, Newstat, Beth O
Formato: Artigo
Lenguaje:Inglês
Publicado: Dove Medical Press 2008
Materias:
Review
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC2727787/
https://ncbi.nlm.nih.gov/pubmed/19707428
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares